Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Information
Welcome
Investor Fact Sheet
Investor Presentations
Media
Top 20 Shareholders
Shareholder Services
Investor FAQs
US Shareholders
Announcements & Reports
ASX Announcements
Publications
Annual Reports
Half Yearly Reports
Quarterly Reports
Research Reports
Contact Us
Contact Us
Email Alerts
Investor Information
Investor Information
>
Welcome
Investor Fact Sheet
Investor Presentations
Media
Top 20 Shareholders
Shareholder Services
Investor FAQs
US Shareholders
Coverage
28-Jun-2021
Amplia Therapeutics and Sydney’s Garvan Institute enter collaboration agreement for pancreatic cancer treatment
2-Jun-2021
Positive data sends Amplia Therapeutics nearly 50 per cent up
18-Mar-2021
Amplia Therapeutics (ASX:ATX) signs agreement with Garvan Institute
17-Mar-2021
Amplia Therapeutics (ASX:ATX) completes single-dose study of AMP945
14-Oct-2020
Joint Cancer Therapeutics CRC/AMPLIA Therapeutics Press Release
9-Oct-2020
Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone
9-Oct-2020
Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone
Previous
1
2